Evidence map›Paper›PMID 38724797›Full record

ReviewAdvances in experimental medicine and biology2024

The Future of Atopic Dermatitis Treatment.

Katie Lovell, Nupur Patel, Saroja Rao, Lindsay C Strowd

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Anti-Inflammatory Activity of Compounds Isolated fromInternational journal of molecular sciences · 2025
    Article
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Katie LovellDepartment of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Nupur PatelDepartment of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Saroja RaoDepartment of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Lindsay C StrowdDepartment of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This chapter thoroughly examines recent breakthroughs in atopic dermatitis (AD) treatment, with a primary focus on the medications in the development pipeline. Biologics agents targeting new interleukin receptors like interleukin-31, interleukin-22, and interleukin-2 are discussed along with the novel pathway looking at the OX40-OX40L interaction. Oral agents and small molecule therapies like Janus kinase inhibitors, sphingosine-1-phosphate modulators, and Bruton's tyrosine kinase inhibitors are also discussed along with the various new topical medications. Newly approved topicals like phosphodiesterase-4 and JAK inhibitors are highlighted while also discussing the potential of tapinarof and emerging microbiome-targeted therapies. Beyond conventional approaches, the chapter touches upon unconventional therapies currently being studied. The goal of this chapter is to discuss new advances in AD treatment from medications in the initial stages of development to those nearing FDA approval.

Indexed as

Dermatitis, AtopicAnimalsBiological ProductsDermatologic AgentsHumansJanus Kinase InhibitorsMolecular Targeted TherapyPhosphodiesterase 4 InhibitorsBiological ProductsDermatologic AgentsJanus Kinase InhibitorsPhosphodiesterase 4 InhibitorsAtopic dermatitisClinical trialsFuture managementFuture treatmentImmune targetsManagementMicrobiomeMonoclonal antibodiesPersonalized careTargeted treatment

Identifiers

PMID38724797

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.